Caring for lifer and health Making contributions to the health of human beings
Release time：2026-06-04 13:44:25 Reading：
On November 27, 2023, Chengdu Jinrui Jiye was granted the National High-tech Enterprise Certificate (Certificate No.: GR202351001833).
The successful accreditation fully recognizes the Company’s strengths in technological R&D and product innovation by relevant national authorities, marking another landmark honor in Jinrui Jiye’s development journey.
About Jinrui Jiye
Jinrui Jiye is an innovative biopharmaceutical enterprise at the clinical development stage. Focused on delivering clinical value, the Company engages in the discovery, development, industrialization and commercialization of differentiated proprietary small-molecule drugs, aiming to provide safe, effective and accessible clinical solutions for severe diseases including various brain tumors, advanced solid tumors, cerebral edema and autoimmune disorders.
Founded over a decade ago, Jinrui Jiye has assembled an in-house independent R&D team and built domestically leading and internationally competitive platforms for liposome and natural medicine research, alongside a GMP-compliant production facility meeting commercial launch standards. Having invested hundreds of millions of RMB, the Company has built a globally competitive pipeline consisting of more than ten innovative anti-cancer candidates to address vast unmet clinical needs and benefit human health worldwide.
Future Outlook
The National High-tech Enterprise certification represents not only an honor but also an obligation. Moving forward, the Company will further strengthen independent innovation, ramp up R&D spending and talent cultivation to boost core competitiveness and contribute to national industrial advancement. Faced with upcoming opportunities and challenges, Jinrui Jiye is fully confident in achieving greater accomplishments.